Document Detail

The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers.
MedLine Citation:
PMID:  17237838     Owner:  NLM     Status:  MEDLINE    
This article provides an update on the use of 2-[(18)F]-fluoro-2-deoxyglucose PET in the follow-up of patients treated for differentiated thyroid carcinoma (DTC). Although DTC recurrence is principally identified by a detectable basal or TSH-stimulated thyroglobulin level, PET helps to localize recurrent disease in patients with normal (131)I total-body scans and other normal anatomic imaging studies. The sensitivity of PET for localization of recurrence ranges from 45% to 100% according to tumor burden and differentiation. Whether PET should be performed after TSH stimulation is unclear, but several studies have reported an increase in the number of lesions detected by uptake of 2-[(18)F]-fluoro-2-deoxyglucose in this setting. Dependent on a center's approach, PET can alter therapeutic management in 9-51% of cases. Furthermore, PET might have a prognostic impact on survival in patients with metastatic disease and aid clinicians in selecting patients who need closer follow-up or aggressive treatment. PET can, therefore, be used advantageously in the follow-up of patients with DTC and can localize disease in patients with elevated thyroglobulin levels, normal total-body scans, and normal findings on conventional imaging modalities. In patients in whom local treatment is planned, especially those with aggressive pathologic variants of thyroid cancer, PET can exclude distant metastases. In patients with metastatic disease, PET can help to identify patients needing closer follow-up.
Sophie Leboulleux; Pamela R Schroeder; Martin Schlumberger; Paul W Ladenson
Related Documents :
22911528 - Body composition and serum levels of adiponectin, vascular endothelial growth factor, a...
2037088 - Are ct infarcts a separate risk factor in patients with transient cerebral ischaemic ep...
10992538 - Non-specific interstitial pneumonia: findings on sequential ct scans of nine patients.
11353298 - Similar pelvic abnormalities on fdg positron emission tomography of different origins.
592068 - Management of major hemoptysis in patients with cystic fibrosis.
2024818 - Differential activation of mixed venous and arterial neutrophils in patients with sepsi...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Nature clinical practice. Endocrinology & metabolism     Volume:  3     ISSN:  1745-8366     ISO Abbreviation:  -     Publication Date:  2007 Feb 
Date Detail:
Created Date:  2007-01-22     Completed Date:  2007-02-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101261798     Medline TA:  Nat Clin Pract Endocrinol Metab     Country:  England    
Other Details:
Languages:  eng     Pagination:  112-21     Citation Subset:  IM    
Department of Nuclear Medicine and Endocrine Tumors at the Institut Gustave Roussy, Villejuif, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Fluorodeoxyglucose F18 / diagnostic use*
Neoplasm Recurrence, Local / blood,  radionuclide imaging*
Neoplasms, Glandular and Epithelial / blood,  radionuclide imaging*
Positron-Emission Tomography / methods*
Radiopharmaceuticals / diagnostic use*
Sensitivity and Specificity
Thyroglobulin / blood
Thyroid Neoplasms / blood,  radionuclide imaging*
Reg. No./Substance:
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18; 9010-34-8/Thyroglobulin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The genetics of the polycystic ovary syndrome.
Next Document:  Clinical lessons from the calcium-sensing receptor.